Evidence for anti-VEGF treatment of diabetic macular edema

F. Bandello, L. Berchicci, C. La Spina, M. Battaglia Parodi, P. Iacono

Research output: Contribution to journalArticlepeer-review


Diabetic macular edema (DME) is the most important cause of vision loss in patients with diabetes mellitus. Diabetic retinopathy has a remarkable impact on public health and on the quality of life of diabetic patients and thus requires special consideration. The first line of treatment remains the management of systemic risk factors but is often insufficient in controlling DME and currently, laser retinal photocoagulation is considered the standard of care. However, laser treatment reduces the risk of moderate visual loss by approximately 50% without guaranteeing remarkable effects on visual improvement. For these reasons, new strategies in the treatment of DME have been studied, in particular the use of anti-vascular endothelial growth factor (anti-VEGF) drugs. VEGF is a pluripotent growth factor that acts as a vasopermeability factor and an endothelial cell mitogen. For this reason, it represents an interesting candidate as a therapeutic target for the treatment of DME. The aim of this article is to review the evidence behind the use of anti-VEGF drugs in the treatment of DME.

Original languageEnglish
Pages (from-to)16-20
Number of pages5
JournalOphthalmic Research
Issue numberSUPPL. 1
Publication statusPublished - Aug 2012


  • Anti-vascular endothelial growth factor
  • Bevacizumab
  • Diabetic macular edema
  • Pegaptanib
  • Ranibizumab
  • VEGF Trap-Eye

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Evidence for anti-VEGF treatment of diabetic macular edema'. Together they form a unique fingerprint.

Cite this